Skip to content


Journal for ImmunoTherapy of Cancer

Open Access

Cyclic dinucleotides (CDNs) reversed T cells tolerance in anti-tumor immunotherapy

  • Juan Fu1,
  • Young Kim2,
  • David Kanne3,
  • Meredith Leong4,
  • Qi Zeng2,
  • Rupashree Sen5,
  • Todd D Amstrong6,
  • Charles G Drake7,
  • Thomas Dubensky4,
  • Drew Pardoll2 and
  • Shekhar Gadkare2
Journal for ImmunoTherapy of Cancer20153(Suppl 2):P268

Published: 4 November 2015


Public HealthTreatment GroupMouse ModelDinucleotideTreg Cell

One important barrier to cancer immunotherapy. We used cyclic dinucleotides (CDNs) and Listeria vaccine and LPS treated HA-specific CD8 tolerance B10. D2 mice. Our results demonstrated T cells IFN-gamma increased in CDNs and Listeria vaccine plus CDNs treatment groups. But CDNs didn't significantly increase Treg cells. The data showed CDNs can reverse established T cell tolerance that improved cancer immunotherapy in the future. We will further explore T cells tolerance in cancer bearing T cell tolerance mice model in vivo.

Authors’ Affiliations

Johns Hopkis Unversity, Baltimore, USA
Johns Hopkins University, Baltimore, USA
Aduro BioTech, Berkeley, USA
Aduro BioTech, Berkely, USA
Johns Hopkins Unversity, Baltimore, USA
Johns Hopins University, Baltimore, USA
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, USA


© Fu et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.